NYSE:DGX - Quest Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$95.85 +0.13 (+0.14 %)
(As of 11/19/2018 03:53 AM ET)
Previous Close$95.85
Today's Range$95.22 - $96.75
52-Week Range$90.31 - $116.49
Volume690,780 shs
Average Volume1.38 million shs
Market Capitalization$13.04 billion
P/E Ratio17.75
Dividend Yield2.09%
Beta0.9
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNYSE:DGX
Previous Symbol
CUSIP74834L10
Phone973-520-2700

Debt

Debt-to-Equity Ratio0.63
Current Ratio1.15
Quick Ratio1.09

Price-To-Earnings

Trailing P/E Ratio17.75
Forward P/E Ratio14.61
P/E Growth1.73

Sales & Book Value

Annual Sales$7.71 billion
Price / Sales1.69
Cash Flow$7.3901 per share
Price / Cash12.97
Book Value$39.43 per share
Price / Book2.43

Profitability

EPS (Most Recent Fiscal Year)$5.40
Net Income$772 million
Net Margins11.30%
Return on Equity15.71%
Return on Assets7.56%

Miscellaneous

Employees45,000
Outstanding Shares136,070,000
Market Cap$13.04 billion
OptionableOptionable

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Friday, August 17th. Stockholders of record on Friday, October 5th will be paid a dividend of $0.50 per share on Monday, October 22nd. This represents a $2.00 annualized dividend and a dividend yield of 2.09%. The ex-dividend date of this dividend is Thursday, October 4th. View Quest Diagnostics' Dividend History.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its Board of Directors has approved a share repurchase program on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 7.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company's management believes its stock is undervalued.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) announced its quarterly earnings results on Tuesday, October, 23rd. The medical research company reported $1.68 EPS for the quarter, meeting the consensus estimate of $1.68. The medical research company earned $1.89 billion during the quarter, compared to analysts' expectations of $1.95 billion. Quest Diagnostics had a return on equity of 15.71% and a net margin of 11.30%. The business's revenue for the quarter was up 1.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.38 earnings per share. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY18 earnings guidance on Tuesday, October, 23rd. The company provided EPS guidance of $6.53-6.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.60. The company issued revenue guidance of ~$7.62 billion, compared to the consensus revenue estimate of $7.71 billion.Quest Diagnostics also updated its FY 2018 guidance to $6.53-6.60 EPS.

What price target have analysts set for DGX?

17 brokerages have issued 12 month price targets for Quest Diagnostics' stock. Their forecasts range from $98.00 to $125.00. On average, they expect Quest Diagnostics' stock price to reach $110.8571 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View Analyst Price Targets for Quest Diagnostics.

What is the consensus analysts' recommendation for Quest Diagnostics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quest Diagnostics.

Has Quest Diagnostics been receiving favorable news coverage?

Media headlines about DGX stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quest Diagnostics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Quest Diagnostics' key competitors?

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 61)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 56)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 55)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 55)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 43)

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.13%), Macquarie Group Ltd. (4.93%), American Century Companies Inc. (3.02%), Fiduciary Management Inc. WI (3.01%), Victory Capital Management Inc. (1.97%) and Dimensional Fund Advisors LP (1.45%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jenne K Britell, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which major investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., York Capital Management Global Advisors LLC, HealthCor Management L.P., Mitsubishi UFJ Trust & Banking Corp, AXA, Schroder Investment Management Group, Fiduciary Management Inc. WI and Candriam Luxembourg S.C.A.. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Robert A Klug and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which major investors are buying Quest Diagnostics stock?

DGX stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Macquarie Group Ltd., Massachusetts Financial Services Co. MA, WINTON GROUP Ltd, Victory Capital Management Inc., Bank of New York Mellon Corp, Stevens Capital Management LP and Credit Suisse AG. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $95.85.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $13.04 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is http://www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  640 (Vote Underperform)
Total Votes:  998
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2018 by MarketBeat.com Staff

Featured Article: What is Cost of Debt?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel